Business

Centuries-old Japanese company carves out a fresh niche.

Oxford Instruments has paid dear for its bold efforts to stretch the boundaries of magnet performance, as Andrea Chipman reports.

Still reeling from the loss of its blockbuster pill Vioxx, Merck is now in court to face its first lawsuit over the drug. Meredith Wadman reports.

The business of writing popular science books is hard to break into — and even harder to make money out of. Tony Reichhardt reports.

Global report highlights how ecology and the environment affect business.

Microchip-makers are starting to look beyond silicon, and what they see, reports Colin Macilwain, is a semiconductor industry of a very different complexion — but not for some time yet.

Technology is no longer limiting the search for genetic diseases.

Sparks of inspiration and close relations with group companies keep Toyota's central research labs motoring along, as Ichiko Fuyuno reports.

The US biotechnology industry's lobby shop is at last making its mark. Its incoming president may have taken some flak for quitting Congress but, as Meredith Wadman discovers, he's relishing the change.